Application Nr Approved Date Route Status External Links
ANDA211229 None None None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Carmustine For Injection Is Indicated As Palliative Therapy As A Single Agent Or In Established Combination Therapy In The Following: - Brain Tumors Glioblastoma, Brainstem Glioma, Medulloblastoma, Astrocytoma, Ependymoma, And Metastatic Brain Tumors. - Multiple Myeloma In Combination With Prednisone. - Relapsed Or Refractory Hodgkin's Lymphoma In Combination With Other Approved Drugs. - Relapsed Or Refractory Non-Hodgkin's Lymphomas In Combination With Other Approved Drugs. Carmustine For Injection Is A Nitrosourea Indicated As Palliative Therapy As A Single Agent Or In Established Combination Therapy With Other Approved Chemotherapeutic Agents In The Following: Brain Tumors Glioblastoma, Brainstem Glioma, Medulloblastoma, Astrocytoma, Ependymoma, And Metastatic Brain Tumors. ( 1 ) Multiple Myeloma-In Combination With Prednisone. ( 1 ) Relapsed Or Refractory Hodgkin's Lymphoma In Combination With Other Approved Drugs. ( 1 ) Relapsed Or Refractory Non-Hodgkin's Lymphomas In Combination With Other Approved Drugs. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Carmustine CARMUSTINE ZINC3830387

Comments